We interrupt regular programming here for an update on a vaccine that many are reporting is 90% effective in early testing. We’re heading deep into the flu season and the President promised some kind of vaccine possibly by as early as the end of 2020, beginning of 2021. That time is coming fast.
With a new president coming, so perhaps might be a new strategy to combat the virus. Will have to wait and see what’s there.
My research has revealed several promising vaccines underway. At the bottom of this post are the details, but first something a bit more wishful thinking to check out.
If what works on ferrets as well as 3D models of humans actually works effectively on, well, real human beings to combat contracting COVID-19, we’re all noses. Er, I mean ears, eyes, you know.
Columbia University researchers have developed a nasal spray that has successfully prevented COVID-19 infections in tests with ferrets as well as a 3D model of human lungs. The lipopeptide (that is, a lipid and peptide combination) prevents the coronavirus from fusing with a target cell’s membrane by blocking a key protein from adopting a necessary shape. It should work immediately and last for at least 24 hours. It’s also affordable, lasts a long time, and doesn’t need refrigeration.Nasal spray might prevent COVID-19 infections | Engadget
Nasal sprays are less invasive than shots, as many people dislike needles. More people dislike dying, so a vaccine however it is delivered will be widespread accepted.
And now for an update on the two most realistic vaccines:
Only two coronavirus vaccine candidates have a realistic shot at winning EUA before the end of the year. BNT162b2, the experimental vaccine developed by Pfizer and BioNTech, probably has the best chance. If all goes well in late-stage testing, the two drugmakers think they’ll be in a position to file for EUA for BNT162b2 by the third week of November.What Are Your Chances of Getting a Coronavirus Vaccine by Year-End?
Seems like Pfizer is on the fastest track to a vaccine — they are the one with the 90% effacy — but if they are approved by the FDA they’ll only be able to vaccinate at best a very small percentage of the population. We’ve been first line workers since this began, so we should be higher up the list, but neither of us are in the health care space, so my guess is we won’t be able to receive the vaccination until some time in 2021, like the rest of America.
A lot of ifs, ands and buts in this post, but there appears to be good news on the horizon.